The Neo-STAT™ Platform – The next generation of Immuno-STATs
The Neo-STAT platform is a variation of the Immuno-STAT™ platform designed with an empty Signal 1 “pocket” enabling easy integration of any tumor-specific protein. Neo-STAT enhances versatility of Cue Biopharma’s biologics to treat a wide range of cancers through “plug-and-play” engineering of bispecific molecules.
Signal 1: An unoccupied peptide antigen cleft in the major histocompatibility peptide complex (pMHC), into which different antigens of interest can easily be added to selectively engage disease-relevant T cells of choice
Signal 2, Fc Backbone, and Peptide Linker: Analogous to the core framework of Immuno-STATs
Proof-of-concept studies showed that Immuno-STATs and Neo-STATs carrying the same peptide antigens led to an equivalent potency in stimulating an immune response, and in particular, the activation and expansion of peptide-specific cytotoxic CD8+ T cells.
>> View data
Key Benefits of the Neo-STAT Platform
- Enables faster and cost-efficient manufacturing
- Increases R&D efficiency by reducing cost of producing clinical grade material
- Enhances platform versatility – Enables targeting of multiple tumor antigens, including post-translationally modified peptides and neo-antigens for personalized therapy